89 related articles for article (PubMed ID: 14519892)
41. Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up.
Cernigliaro C; Sansa M; Vitrella G; Verde A; Bongo AS; Giuliani L; Novelli E
Cardiology; 2010; 115(1):77-86. PubMed ID: 19887796
[TBL] [Abstract][Full Text] [Related]
42. [Prevention of instant restenosis after coronary angioplasty by implantation of rapamycin-coated stents].
Hansen PR; Abildgaard U; Galløe AM; Kassis E
Ugeskr Laeger; 2001 Mar; 163(12):1714. PubMed ID: 11284414
[No Abstract] [Full Text] [Related]
43. Indirect evidence for a role of a subpopulation of activated neutrophils in the remodelling process after percutaneous coronary intervention.
Costa MA; de Wit LE; de Valk V; Serrano P; Wardeh AJ; Serruys PW; Sluiter W
Eur Heart J; 2001 Apr; 22(7):580-6. PubMed ID: 11259145
[TBL] [Abstract][Full Text] [Related]
44. Systemic immunosuppressive therapy inhibits in-stent restenosis in patients with renal allograft.
Jung JH; Min PK; Kim JY; Park S; Choi EY; Ko YG; Choi D; Jang Y; Shim WH; Cho SY
Catheter Cardiovasc Interv; 2006 Oct; 68(4):567-73. PubMed ID: 16969853
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis.
Kuchulakanti P; Waksman R
Drugs; 2004; 64(21):2379-88. PubMed ID: 15481997
[TBL] [Abstract][Full Text] [Related]
46. Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting.
Rosa WC; Campos AH; Lima VC
Braz J Med Biol Res; 2010 Aug; 43(8):786-93. PubMed ID: 20725695
[TBL] [Abstract][Full Text] [Related]
47. Rapamycin in cardiovascular medicine.
Ruygrok PN; Muller DW; Serruys PW
Intern Med J; 2003 Mar; 33(3):103-9. PubMed ID: 12603583
[TBL] [Abstract][Full Text] [Related]
48. The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2).
Tamai H; Katoh K; Yamaguchi T; Hayakawa H; Kanmatsuse K; Haze K; Aizawa T; Nakanishi S; Suzuki S; Suzuki T; Takase S; Nishikawa H; Katoh O
Am Heart J; 2002 Mar; 143(3):506-13. PubMed ID: 11868058
[TBL] [Abstract][Full Text] [Related]
49. Oral Health of Patients Undergoing Percutaneous Coronary Intervention-A Possible Link between Periodontal Disease and In-Stent Restenosis.
Nagy FT; Gheorghita D; Dharmarajan L; Braunitzer G; Achim A; Ruzsa Z; Antal MÁ
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240930
[No Abstract] [Full Text] [Related]
50. Nanoparticles responsive to the inflammatory microenvironment for targeted treatment of arterial restenosis.
Feng S; Hu Y; Peng S; Han S; Tao H; Zhang Q; Xu X; Zhang J; Hu H
Biomaterials; 2016 Oct; 105():167-184. PubMed ID: 27522252
[TBL] [Abstract][Full Text] [Related]
51. Stent-based immunosuppressive therapies for the prevention of restenosis.
Aggarwal M; Tsao PS; Yeung A; Carter AJ
Cardiovasc Radiat Med; 2003; 4(2):98-107. PubMed ID: 14581091
[No Abstract] [Full Text] [Related]
52. Effect of Low-Dose Rapamycin on Senescence Markers and Physical Functioning in Older Adults with Coronary Artery Disease: Results of a Pilot Study.
Singh M; Jensen MD; Lerman A; Kushwaha S; Rihal CS; Gersh BJ; Behfar A; Tchkonia T; Thomas RJ; Lennon RJ; Keenan LR; Moore AG; Kirkland JL
J Frailty Aging; 2016; 5(4):204-207. PubMed ID: 27883166
[TBL] [Abstract][Full Text] [Related]
53. CLAPO syndrome: Effective response to treatment with oral rapamycin.
González-Hermosa MR; Guerra E; Tuduri I; Vicente I; López-Almaraz R
Dermatol Ther; 2019 Jul; 32(4):e12991. PubMed ID: 31172613
[TBL] [Abstract][Full Text] [Related]
54. A meta-analytical approach for the treatment of in-stent restenosis.
Mercado N; Serruys PW
Eur Heart J; 2003 Feb; 24(3):217-8. PubMed ID: 12590898
[No Abstract] [Full Text] [Related]
55. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.
Urfer SR; Kaeberlein TL; Mailheau S; Bergman PJ; Creevy KE; Promislow DEL; Kaeberlein M
Geroscience; 2017 Apr; 39(2):117-127. PubMed ID: 28374166
[TBL] [Abstract][Full Text] [Related]
56. Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application.
Liu Y; Yang F; Zou S; Qu L
Front Pharmacol; 2018; 9():1520. PubMed ID: 30666207
[TBL] [Abstract][Full Text] [Related]
57. The Effects of Rapamycin on the Proliferation, Migration, and Apoptosis of Human Tracheal Fibroblasts (HTrF) and Human Tracheal Epithelial Cells (HTEpiC).
Liu Y; Zhang J; Long J; Qiu X; Wang T; Wang J
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160060
[TBL] [Abstract][Full Text] [Related]
58. Corrigendum to "Extravascular rapamycin film inhibits the endothelial-to-mesenchymal transition through the autophagy pathway to prevent vein graft restenosis" [Biomater. Adv. 137, 2022, 212836].
Chu T; Dai C; Li X; Gao L; Yin H; Ge J
Biomater Adv; 2023 Feb; 145():213237. PubMed ID: 36571984
[No Abstract] [Full Text] [Related]
59. [Angiogram of the month].
Gil RJ; Rzezak J
Kardiol Pol; 2002 Nov; 57(11):481-3. PubMed ID: 12961016
[No Abstract] [Full Text] [Related]
60. [Angiogram of the month].
Gil RJ; Rzezak J
Kardiol Pol; 2002 Dec; 57(12):594-6; discussion 596. PubMed ID: 12960993
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
